why choose us

🌐 Go to WebHealthNetwork.com
Go to Consumers Chat
300×250 Ad Slot

Drug FDA Status

Showing 80 of 139 result(s) (Page 8 of 14)
Drug Name: Ojemda

Active Ingredient: tovorafenib

Approval Date: 2024-04-23

Description: To treat relapsed or refractory pediatric low-grade glioma
Drug Trials Snapshot

Drug Name: Anktiva

Active Ingredient: nogapendekin alfa inbakicept-pmln

Approval Date: 2024-04-22

Description: To treat bladder cancer
Drug Trials Snapshot

Drug Name: Lumisight

Active Ingredient: pegulicianine

Approval Date: 2024-04-17

Description: To use as an optical imaging agent for the detection of cancerous tissue
Drug Trials Snapshot

Drug Name: Zevtera

Active Ingredient: ceftobiprole medocaril sodium

Approval Date: 2024-04-03

Description: To treat certain bloodstream infections, bacterial skin and associated tissue infections, and community-acquired bacterial pneumonia
Press Release
Drug Trials Snapshot

Drug Name: Voydeya

Active Ingredient: danicopan

Approval Date: 2024-03-29

Description: To treat extravascular hemolysis with paroxysmal nocturnal hemoglobinuria
Drug Trials Snapshot

Drug Name: Vafseo

Active Ingredient: vadadustat

Approval Date: 2024-03-27

Description: To treat anemia due to chronic kidney disease
Drug Trials Snapshot

Drug Name: Winrevair

Active Ingredient: sotatercept-csrk

Approval Date: 2024-03-26

Description: To treat pulmonary arterial hypertension
Drug Trials Snapshot

Drug Name: Duvyzat

Active Ingredient: givinostat

Approval Date: 2024-03-21

Description: To treat Duchenne muscular dystrophy in individuals aged 6 years and older
Press Release
Drug Trials Snapshot

Drug Name: Tryvio

Active Ingredient: aprocitentan

Approval Date: 2024-03-19

Description: To treat hypertension
Drug Trials Snapshot

Drug Name: Rezdiffra

Active Ingredient: resmetirom

Approval Date: 2024-03-14

Description: To treat noncirrhotic non-alcoholic steatohepatitis with moderate to advanced liver scarring
Press Release
Drug Trials Snapshot

300×250 Ad Slot